Literature DB >> 17875425

Hyperosmotic induction of mitogen-activated protein kinase scaffolding.

Thomas L Hilder1, Michael H Malone, Gary L Johnson.   

Abstract

Eukaryotic cells respond to hyperosmotic conditions by expunging water from the cell, leading to cell shrinkage. This is counteracted by adaptive responses that restore cell volume and strengthen the cytoskeletal architecture. In the budding yeast Saccharomyces cerevisiae, this response is mediated primarily by the mitogen-activated protein kinase (MAPK) cascade CDC42-STE50-STE11-Pbs2-Hog1. In mammalian cells, MAPK scaffold proteins facilitate the efficiency of signaling within the cascade by placing a kinase near its substrate and also regulate the subcellular localization of the signaling. Our laboratory has discovered a scaffold that coordinates the analogous Hog1 signal in mammalian cells, termed OSM (osmosensing scaffold for MEKK3). OSM organizes a complex consisting of the small GTPase Rac, MEKK3, and MKK3 for the activation of p38 MAPK. Interactions among OSM, Rac, and MEKK3 are augmented in response to sorbitol and are also localized to membrane ruffles, sites of rapid actin turnover. Suppression of the expression of OSM or MEKK3 by RNA interference strongly inhibits the sorbitol-dependent activation of p38. Furthermore, mutations in OSM were concurrently found to cause cerebral cavernous malformations (CCM), a disease of the central nervous system characterized by thin-walled, leaky blood vessels that become hemorrhagic. Our laboratory has also demonstrated that Krit1, another gene harboring mutations that lead to CCM, binds OSM and its interaction is enhanced in response to sorbitol in a similar manner as the MEKK3-OSM interaction. This chapter describes the cell biological and biochemical methods used for assaying protein-protein interactions in live cells using fluorescence resonance energy transfer, in vitro kinase assays for MEKK3-MKK3-p38 pathway members, and gene suppression by RNA interference to study hyperosmotic stress-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875425     DOI: 10.1016/S0076-6879(07)28017-6

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  6 in total

Review 1.  Cerebral cavernous malformation proteins at a glance.

Authors:  Kyle M Draheim; Oriana S Fisher; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2014-01-30       Impact factor: 5.285

2.  Tight interconnection and multi-level control of Arabidopsis MYB44 in MAPK cascade signalling.

Authors:  Helene Persak; Andrea Pitzschke
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

3.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

4.  Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome.

Authors:  Carlos Guerrero-Bosagna; Matthew Settles; Ben Lucker; Michael K Skinner
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

5.  Receptor for advanced glycation end products aggravates cognitive deficits in type 2 diabetes through binding of C-terminal AAs 2-5 to mitogen-activated protein kinase kinase 3 (MKK3) and facilitation of MEKK3-MKK3-p38 module assembly.

Authors:  Xiao-Yan Zhou; Chang-Jiang Ying; Bin Hu; Yu-Sheng Zhang; Tian Gan; Yan-Dong Zhu; Nan Wang; An-An Li; Yuan-Jian Song
Journal:  Aging Cell       Date:  2022-01-26       Impact factor: 9.304

Review 6.  Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation.

Authors:  Shu Wei; Ye Li; Sean P Polster; Christopher R Weber; Issam A Awad; Le Shen
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.